Zobrazeno 1 - 10
of 18 239
pro vyhledávání: ''
Autor:
N Manuelipillai, E Veysey
Publikováno v:
Clinical and Experimental Dermatology. 47:770-773
Guidelines for isotretinoin for the treatment of acne vulgaris (AV) do not exist in Australia but are utilised in United Kingdom (UK) (1), Europe (EU) (2) and the United States of America (USA) (3). The Australasian College of Dermatologists (ACD) de
Autor:
Hugo Navarrete, Manuel Echeverría, Camilo Zurita, Gabriela Sevillano, Ariane Paz y Miño, Vicente Peñaherrera, Jeannete Zurita
Publikováno v:
Journal of Applied Microbiology. 132:2694-2704
Aims We described the presence of Helicobacter pylori (HP) and estimated the prevalence of primary and secondary resistance using molecular detection in gastric biopsies of Ecuadorian patients. Methods and Results 66.7% (238/357) of the patients demo
Publikováno v:
Clinical and Experimental Dermatology. 47:667-674
Summary Thalidomide is a medication that has been in existence for over half a century, and has proven to be useful and effective in severe dermatological conditions. For dermatologists, the ability of thalidomide to reduce the levels of the cytokine
Publikováno v:
Journal of Antimicrobial Chemotherapy. 77:1413-1416
Background Ivermectin is an antiparasitic drug being investigated in clinical trials for the prevention of COVID-19. However, there are concerns about the quality of some of these trials. Objectives To conduct a meta-analysis with randomized controll
Publikováno v:
Alzaid, M, Al-Naseem, A, Al-Niaimi, F & Ali, F R 2022, ' Topical timolol in dermatology : infantile haemangiomas and beyond ', Clinical and Experimental Dermatology, vol. 47, no. 5, pp. 819-832 . https://doi.org/10.1111/ced.15021
Timolol, a non-selective β-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology especially after its use in the management of infantile hemangiomas. Its effects are mainly due to vasoconstriction, inhibi
Autor:
Nadezda Machkova, Martin Lukas, Kristyna Kastylova, D. Duricova, Marta Kostrejová, Katarina Mitrova, Vladimír Teplan, Milan Lukáš, Martin Vašátko, Kristyna Kubickova, Veronika Hruba, Karin Cerna
Publikováno v:
Inflammatory Bowel Diseases. 28:1506-1512
Background Patients with inflammatory bowel disease (IBD) on immune-modifying treatment could be at an increased risk for severe coronavirus disease 2019 (COVID-19); thus, data on the efficacy and safety of severe acute respiratory syndrome coronavir
Autor:
Yohei Kirino, Toshihiro Tono, Hirotoshi Kikuchi, Shunsei Hirohata, Mitsuhiro Takeno, Tetsuji Sawada, Yoshiya Tanaka, Kunihiro Yamaoka, Hiroko Nagafuchi
Publikováno v:
Modern Rheumatology. 32:1146-1152
Objectives Approximately 30–60% of Behçet’s disease patients exhibit joint symptoms. The aim of this study was to determine the clinical characteristics of such patients in Japan. Methods This study retrospectively analyzed 151 Behçet’s disea
Autor:
Russell R. Kempker, Charles A. Peloquin, Henry M. Blumberg, Zaza Avaliani, Jeffrey M. Collins, Shorena Sabanadze, Maia Kipiani, Mariam Gujabidze, Tinatin Bakuradze, Alison Smith, Mohammad H. Al-Shaer, Teona Avaliani
Publikováno v:
Clin Infect Dis
Background The ability of antituberculosis drugs to cross the blood–brain barrier and reach the central nervous system is critical to their effectiveness in treating tuberculosis meningitis (TBM). We sought to fill a critical knowledge gap by provi
Autor:
Atefeh Bonyadi, Fariborz Mansour-Ghanaei, Farhang Babamahmoodi, Esmat Radmanesh, Hadiseh Hosamirudsari, Javad Khodadadi, Sara Sayar, Zeinab Mehrabi, Amir Reza Bahadori, Shahin Merat, Minoo Moghimi, Gholamali Eslami, Hashem Mousavi, Lotfollah Davoodi, Mona Ebrahimzadeh, Farahnaz Joukar, Amir Anushiravani, Ali Ali Asgari, Ali Reza Davoudi Badabi, Elham Barahimi, Saeed Jelvay, Zahra Poormontaseri, Aida Zeinali, Nasim Khajavirad, Minoosh Shabani, Hamideh Abbaspour Kasgari, Zohreh Azarkar, Rohollah Moslemi, Ahmad Hormati, Azadeh Ebrahimzadeh, Hani Esmaeilian, Shokrollah Salmanzadeh, Elham Akbarpour, Lili Rezaie Keikhaie, Kaitlyn McCann, Amir Mohammad Shabani, Abdolali Tousi, Mohammad Abdollahi, Sara Mobarak, Mohammadreza Naghipour, Hadi Mirzaei, Mohammadreza Salehi, Shervin Shokouhi, Bryony Simmons, Morteza Mobarak, Helia Nateghi Baygi, Jacob Levi, Mehdi Hassaniazad, Andrew Hill, Zahra Arizavi, Nasrollah Hasooni Bahrini, Seyed Ali Dehghan Manshadi, Fatemeh Dehghani, Hannah Wentzel, Hossein Pourmasoomi, Masoome Noori Jangi, Shoeleh Yaghoubi, Alireza Nateghi Baygi, Mehdi Salasi, Farnaz Zolfaghari, Sara Yeganeh, Elmira Azimi, Jalal Karimi, Hafez Fakheri, Mahdi Afshari, Tofigh Yaghubi Kalurazi, Anahita Sadeghi, Farshid Abedi, Sajedeh Mousaviasl, Zahra Nekoukar, Dorsa Merat, Masood Ziaee
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background: The combination of sofosbuvir (SOF) and daclatasvir (DCV) has shown preliminary efficacy for patients with COVID-19 in five open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir and da
Publikováno v:
American Journal of Health-System Pharmacy. 79:467-471
Purpose Stenotrophomonas maltophilia has emerged as a critical opportunistic pathogen associated with significant morbidity and mortality. Tetracycline derivatives have been recognized as alternative treatment options, but they have varied pharmacoki